JWA
MYGN icon

JFS Wealth Advisors’s Myriad Genetics MYGN Stock Holding History

JFS Wealth Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$42 – 1971
2024
Q4 		$42 Sell
3
-39
-93% -$720 ﹤0.01% 1912
2024
Q3 		$1.15K Buy
42
+6
+17% +$162 ﹤0.01% 1664
2024
Q2 		$881 Hold
36
– – ﹤0.01% 1693
2024
Q1 		$768 Buy
36
+17
+89% +$365 ﹤0.01% 1718
2023
Q4 		$364 Buy
19
+7
+58% +$121 ﹤0.01% 1844
2023
Q3 		$193 Sell
12
-14
-54% -$266 ﹤0.01% 1866
2023
Q2 		$603 Hold
26
– – ﹤0.01% 1730
2023
Q1 		$604 Buy
26
+6
+30% +$122 ﹤0.01% 1694
2022
Q4 		$290 Buy
20
+11
+122% +$205 ﹤0.01% 1805
2022
Q3 		$0 Buy
9
+2
+29% +$46 ﹤0.01% 1858
2022
Q2 		$0 Sell
7
-11
-61% -$228 ﹤0.01% 1868
2022
Q1 		$0 Buy
18
+12
+200% +$307 ﹤0.01% 1912
2021
Q4 		$0 Buy
+6
New +$174 ﹤0.01% 1823

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JFS Wealth Advisors's MYGN Position: Q1 2025 in Review

JFS Wealth Advisors sold out of Myriad Genetics (MYGN) in Q1 2025, closing a stake of 3 shares — an estimated $42 sold.

JFS Wealth Advisors first reported a position in MYGN in Q4 2021 and held it in 13 quarters. The position peaked at $1.15K in Q3 2024. 228 funds tracked by Wall St. Rank hold MYGN as of Q1 2025.

  • JFS Wealth Advisors reported no remaining Myriad Genetics position as of Q1 2025 after selling out during the quarter.
  • JFS Wealth Advisors sold 3 Myriad Genetics shares in Q1 2025, an estimated $42.
  • JFS Wealth Advisors first reported a position in Myriad Genetics in Q4 2021 and held it in 13 quarters.
  • JFS Wealth Advisors's Myriad Genetics position peaked at $1.15K in Q3 2024.
  • 228 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2025.

Based on JFS Wealth Advisors's 13F filing for Q1 2025, filed 22 Apr 2025.